Home

Keyvisual giving

 

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM Radiotheranostics Satellite Symposium.

Prof M Caplin, Prof P Ruszniewski, Dr G Nicolas and Dr S Glasberg discussed about “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” at ENETS 2019

Watch the Video >>

Michael Lee-Chin joins the ITM Supervisory Board

ITM announced today the appointment of Michael Lee-Chin to its supervisory board, starting May 23, 2019.

Read more

Press Releases

ITM builds new production site in Munich Area

ITM announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177…

Read more

Press Releases

ITM and United Imaging team up in strategic partnership to cover Chinese and global cancer imaging markets

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

Press Releases

View all news »

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>